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Background: The Smyth line (SL) chicken is the only animal model for autoimmune vitiligo that spontaneously
displays all clinical and biological manifestations of the human disorder. To understand the genetic components
underlying the susceptibility to develop SL vitiligo (SLV), whole genome resequencing analysis was performed in
SLV chickens compared with non-vitiliginous parental Brown line (BL) chickens, which maintain a very low incidence
rate of vitiligo.
Results: Illumina sequencing technology and reference based assembly on Red Jungle Fowl genome sequences
were used. Results of genome resequencing of pooled DNA of each 10 BL and SL chickens reached 5.1x and 7.0x
coverage, respectively. The total number of SNPs was 4.8 and 5.5 million in BL and SL genome, respectively.
Through a series of filtering processes, a total of ~1 million unique SNPs were found in the SL alone. Eventually of
the 156 reliable marker SNPs, which can induce non-synonymous-, frameshift-, nonsense-, and no-start mutations in
amino acid sequences in proteins, 139 genes were chosen for further analysis. Of these, 14 randomly chosen SNPs
were examined for SNP verification by PCR and Sanger sequencing to detect SNP positions in 20 BL and 70 SL
chickens. The results of the analysis of the 14 SNPs clearly showed differential frequencies of nucleotide bases in
the SNP positions between BL and SL chickens. Bioinformatic analysis showed that the 156 most reliable marker
SNPs included genes involved in dermatological diseases/conditions such as ADAMTS13, ASPM, ATP6V0A2, BRCA2,
COL12A1, GRM5, LRP2, OBSCN, PLAU, RNF168, STAB2, and XIRP1. Intermolecular gene network analysis revealed that
candidate genes identified in SLV play a role in networks centered on protein kinases (MAPK, ERK1/2, PKC, PRKDC),
phosphatase (PPP1CA), ubiquitinylation (UBC) and amyloid production (APP).
Conclusions: Various potential genetic markers showing amino acid changes and potential roles in vitiligo development
were identified in the SLV chicken through genome resequencing. The genetic markers and bioinformatic interpretations
of amino acid mutations found in SLV chickens may provide insight into the genetic component responsible for the
onset and the progression of autoimmune vitiligo and serve as valuable markers to develop diagnostic tools to detect
vitiligo susceptibility.Background
Vitiligo is an acquired hypomelanotic disorder character-
ized by circumscribed depigmented macules in the skin
resulting from the loss of melanocytes. Autoimmunity
has been identified as the major etiological factor in vitiligo,
although many other factors including infections, stress,
neural abnormalities, aberrant melanocyte function, and* Correspondence: bkong@uark.edu
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unless otherwise stated.genetic susceptibility have been implicated [1]. The Smyth
line (SL) chicken is the only animal model for autoimmune
vitiligo that spontaneously displays all clinical and biological
manifestations of the human disorder [2,3]. Like other
autoimmune diseases, SL vitiligo (SLV) is multi-factorial in
nature and involves the interplay of genetic, immune sys-
tem, and environmental-factors. SLV susceptibility is mani-
fested in part in an inherent melanocyte defect and loss of
melanocytes is due to melanocyte-specific cell-mediated
and humoral immune activities [2,3].d. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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humans to understand the role of genetic components
in a variety of autoimmune diseases including vitiligo
have identified hundreds of loci harboring risk alleles
[4]. Several GWAS results identified vitiligo susceptible
loci in human populations [5-10]. However, most sus-
ceptible loci identified by GWAS results were found
in regulatory regions of gene expression, therefore the
identified associations were not sufficient to identify the
causal gene or deduce alterations caused by risk variants,
which generally do not induce profound changes to
genes (e.g. coding sequence changes, deletions, or dupli-
cations). Recently, the encyclopedia of DNA elements
(ENCODE) of mammalian species suggested that ~90%
of disease associated genetic variations in human lie in
noncoding regions, while only ~10% of variations in
coding regions were causative mutations associated with
human disease [11,12]. Nevertheless, the identification
of potential coding mutations that alter protein func-
tionalities is a prerequisite process to understand disease
etiology. Moreover, the functional study of candidate
genetic risk factors is almost impossible without appro-
priate model systems.
The SL chicken is an excellent model to conduct a func-
tional verification study of candidate genes that underlie
genetic susceptibility for vitiligo due to the tractable,
definite phenotype, the high vitiligo incidence in the popu-
lation (80-90%), the feasibility of in vivo characterization
and the relatively short generation time. Recently,
microarray analysis examined global gene expression
during SLV development and provided comprehensive
information at the transcriptome level that supported
the multifactorial etiology of vitiligo [13]. In this study,
whole genome resequencing analysis using an Illumina
platform was performed to more deeply investigate the
genetic aspects of SLV expression in comparison with
the parental Brown line (BL) of chickens from which
the SL was originally derived. BL chickens retain viti-
ligo susceptibility but with a very low (0 – 2%) inci-
dence rate of vitiligo development [2,3], although none
of the BL chickens used in this study had vitiligo. Mil-
lions of single nucleotide polymorphisms (SNP) were
identified by genome resequencing and only potentially
causal genes containing non-synonymous mutations
that can induce amino acid changes in proteins were
focused on in this study.Table 1 Results of Illumina sequencing and assembly
Line Reads numbers Total # of reads used for alignment
BL (P) 1 62,764,368 50,536,831
SL2 88,525,266 69,886,110
1(P) means the parental line, no vitiligo.
2 SL, with vitiligo.Results and discussion
Genome resequencing for BL and SL chickens
Genome sequencing of pooled DNA from 10 non-
vitiliginous BL and SL chickens each with confirmed
SLV produced ~63 and 89 million sequence reads of
200 bp, respectively (Table 1). Of those, ~80% of the
reads were used for sequence alignment, while 20% of
sequence reads were not aligned. Therefore, genome
coverage for BL and SL reached 5.1x and 7.0x, respect-
ively, of the Red Jungle Fowl chicken genome. The total
number of SNPs was 4.8 and 5.5 million (~0.5% of tem-
plate genome) for the BL and SL genome, respectively.
The large number of SNPs per examined chicken line
was based on data of at least 2 read coverage depths
(number of read counts per nucleotide location). Most
SNPs were found on the larger chromosomes (Chr), in-
cluding Chr 1 through 5 and Z (sex chromosome) (data
not shown). To identify genetic biomarkers that are re-
sponsible for the incidence of SLV, unique SNPs that are
found in SL only were selected by removing SNPs that
overlapped with those found in the parental BL. Then,
mutations with ≥75% SNP rates were chosen as reliable
marker SNPs. Since the objective of this study was to
identify mutational SNPs uniquely found in SL com-
pared to the parental BL, the filtering process used did
not involve a typical SNP calling and filtering method
based on quality score (Q call column in Additional file
1: Table S1) [14]. Instead, SNP filtering was conducted
by removing overlapping SNPs found in both BL and
SL, and applying fixed %SNP rates (≥75%) as described
in Methods. As a result, a total of ~1 million unique
SNPs were identified throughout the SL chicken genome
(Figure 1). Over 100,000 SNPs were found in Chr 1, 2, 3,
and Z while Chr 32 did not contain any unique SNPs for
SL. When SNPs were grouped by the feature types
of chromosome regions, ~50% of SNPs were in the
intergenic (heterochromatic) regions and 13,710 SNPs
were found in CDS sequences (protein coding regions)
(Figure 2). Most genes containing SNPs in regulatory re-
gions, not in CDS regions, identified by human GWAS
studies were also observed to contain unique SNPs in
the current SL study (data not shown). Around 60% of
SL SNPs in protein coding CDS regions were synonym-
ous mutations that did not induce amino acid changes.
To identify potentially causal mutations that induce pro-
tein coding alterations, SNP analysis focused on SNPsTotal # of reads not aligned Coverage Total # of SNP
9,480,794 5.1x 4,846,132
14,225,577 7.0x 5,465,994
Figure 1 Number of unique SNPs per chromosome found in vitiliginous SL chickens compared to non-vitiliginous BL chickens. Numbers are
indicated for bars not clearly visible.
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approach, a total of 3518 SNPs were identified that
could induce non-synonymous-, frameshift-, nonsense-,
and no-start-changes in the CDS region (Figure 2 and
Additional file 1: Table S1), suggesting that the 3518
SNPs are part of the genetic components in functional
protein coding regions that may drive the high incidence
rate of SLV. Of the 3518 candidate SNPs that are associ-
ated with amino acid changes, SNPs showing ≥10 read
depths (considered to be more reliable candidate genetic
markers) were chosen for the further analysis. Using thisFigure 2 Summary of SNPs in SLV. A) Number of SNPs categorized by c
type of amino acid sequence changes.approach, 195 SNPs remained (data not shown). To re-
duce false positives due to possible errors in the assem-
bly process, re-scanning of each SNP position for the
195 potentially more reliable protein coding SNPs was
conducted using the Seqman-Pro viewer program. This
process yielded 156 more reliable SNPs that were chosen
as candidate marker SNPs for further analysis (Table 2).
SNP validation using PCR and Sanger sequencing
Since pooled DNA samples of 10 chickens for each line
were used for genome sequencing, individual SNPs werehromosomal region in SL chickens. B) Number of SNPs categorized by
Table 2 The 156 reliable marker SNPs that induced amino acid changes showing ≥10 read depths
Contig ID c Ref Pos Ref base Called base Impact SNP% Gene symbol DNA change AA Change Depth A Cnt C Cnt G Cnt T Cnt Del
NC_006088 1 12587537 C T N-Syn 0.80 FGL2 c.368C > T T123I 10 0 - 0 8 0
NC_006088 1 24296415 G C N-Syn 1.00 CTTNBP2 c.2600G > C R867P 12 0 12 - 0 0
NC_006088 1 33755434 G A N-Syn 0.91 TBC1D30 c.304G > A V102I 11 10 0 - 0 0
NC_006088 1 34386453 G A N-Syn 1.00 HELB c.2342G > A G781E 12 12 0 - 0 0
NC_006088 1 34386455 C T N-Syn 1.00 HELB c.2344C > T R782W 12 0 - 0 12 0
NC_006088 1 45803846 A G N-Syn 1.00 LOC417921 c.1457A > G Q486R 11 - 0 11 0 0
NC_006088 1 45804772 T A N-Syn 0.92 LOC417921 c.1700 T > A I567K 13 12 1 0 - 0
NC_006088 1 54936701 G T N-Syn 0.80 STAB2 c.6155G > T A2052D 10 0 0 - 8 0
NC_006088 1 67320079 C C|A N-Syn 0.77 CASC1 c.[949C > C] + [949C > A] V317V, V317F 13 10 - 0 0 0
NC_006088 1 82856208 G T N-Syn 1.00 CD200R1 c.197G > T R66L 11 0 0 - 11 0
NC_006088 1 88049869 C T N-Syn 0.90 LOC418423 c.229C > T V77I 10 0 - 0 9 0
NC_006088 1 88157238 C T N-Syn 1.00 CGGBP1 c.428C > T R143Q 10 0 - 0 10 0
NC_006088 1 105941417 T C N-Syn 0.90 SETD4 c.1186 T > C I396V 10 0 9 0 - 0
NC_006088 1 107377588 C G N-Syn 0.92 LCA5L c.1331C > G G444A 13 0 - 12 0 0
NC_006088 1 108406755 T T|C N-Syn 0.77 LOC770616 c.[37 T > T] +
[37 T > C]
M13M, M13V 13 0 10 0 - 0
NC_006088 1 108764081 C T N-Syn 0.91 UBASH3A c.1144C > T L382F 11 0 - 0 10 0
NC_006088 1 109036880 G T N-Syn 1.00 CBS c.1492G > T Q498K 10 0 0 - 10 0
NC_006088 1 112264749 A G N-Syn 1.00 OTC c.5A > G L2P 12 - 0 12 0 0
NC_006088 1 112303781 A G N-Syn 1.00 RPGR c.2359A > G I787V 13 - 0 13 0 0
NC_006088 1 112303950 G A N-Syn 1.00 RPGR c.2528G > A G843E 10 10 0 - 0 0
NC_006088 1 121737171 G A N-Syn 1.00 FANCB c.1988G > A R663K 12 12 0 - 0 0
NC_006088 1 121737188 C A N-Syn 1.00 FANCB c.2005C > A L669M 12 12 - 0 0 0
NC_006088 1 133392696 A G N-Syn 1.00 MFSD9 c.790A > G F264L 11 - 0 11 0 0
NC_006088 1 137555484 C T|C N-Syn 0.79 MYO16 c.[1232C > T] + [1232C > C] T411T, T411I 14 0 - 0 11 0
NC_006088 1 138584430 C T N-Syn 0.90 ANKRD10 c.551C > T R184H 10 0 - 0 9 0
NC_006088 1 152732014 A G N-Syn 1.00 RNF219 c.794A > G Q265R 10 - 0 10 0 0
NC_006088 1 153202063 C T N-Syn 1.00 SLAIN1 c.1486C > T G496S 11 0 - 0 11 0
NC_006088 1 166907615 G C N-Syn 0.90 NUFIP1 c.925G > C Q309E 10 0 9 - 0 0
NC_006088 1 169375045 A G N-Syn 0.91 SERPINE3 c.254A > G H85R 11 - 0 10 0 0
NC_006088 1 173852809 T C N-Syn 1.00 BRCA2 c.355 T > C T119A 10 0 10 0 - 0
NC_006088 1 176891377 A G N-Syn 1.00 SACS c.6235A > G I2079V 11 - 0 11 0 0
NC_006088 1 177772554 C A N-Syn 0.86 EFHA1 c.659C > A A220D 14 12 - 0 0 0
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Table 2 The 156 reliable marker SNPs that induced amino acid changes showing ≥10 read depths (Continued)
NC_006088 1 177772568 G A N-Syn 0.86 EFHA1 c.673G > A V225I 14 12 0 - 0 0
NC_006088 1 178541726 G T N-Syn 0.92 CENPJ c.2041G > T V681L 12 0 0 - 11 0
NC_006088 1 187399843 G A N-Syn 0.90 GRM5 c.2842G > A A948T 10 9 0 - 0 0
NC_006088 1 194954389 A G N-Syn 1.00 RNF169 c.992A > G V331A 10 - 0 10 0 0
NC_006089 2 2046630 C T N-Syn 1.00 CCDC13 c.860C > T S287N 12 0 - 0 12 0
NC_006089 2 2059597 T C N-Syn 1.00 CCDC13 c.209 T > C D70G 11 0 11 0 - 0
NC_006089 2 2141930 A G N-Syn 0.90 OBSCN c.17225A > G I5742T 10 - 0 9 0 0
NC_006089 2 2155796 T C N-Syn 1.00 OBSCN c.14875 T > C N4959D 11 0 11 0 - 0
NC_006089 2 4669968 C T N-Syn 0.90 DLEC1 c.1592C > T A531V 10 0 - 0 9 0
NC_006089 2 4948035 C T N-Syn 1.00 XIRP1 c.4696C > T A1566T 11 0 - 0 11 0
NC_006089 2 7746258 C - Frameshift 1.00 LOC100859401 c.388C > - Y129fs 10 0 - 0 0 10
NC_006089 2 20725367 C A N-Syn 1.00 DBF4 c.1114C > A P372T 11 11 - 0 0 0
NC_006089 2 21576571 C T N-Syn 0.90 C2H7orf63 c.962C > T T321M 10 0 - 0 9 0
NC_006089 2 23984791 G A N-Syn 0.90 PON2 c.521G > A P174L 10 9 0 - 0 0
NC_006089 2 26789159 T C N-Syn 1.00 VWDE c.2678 T > C N893S 11 0 11 0 - 0
NC_006089 2 42356129 C T N-Syn 1.00 LOC100857506 c.757C > T P253S 12 0 - 0 12 0
NC_006089 2 43749632 C T N-Syn 1.00 TGM4 c.160C > T A54T 10 0 - 0 10 0
NC_006089 2 47501151 C A N-Syn 1.00 SEPT7 c.764C > A G255V 10 10 - 0 0 0
NC_006089 2 48103938 C T N-Syn 1.00 BMPER c.1957C > T V653I 11 0 - 0 11 0
NC_006089 2 67476715 T A N-Syn 1.00 MYLK4 c.2071 T > A I691L 12 12 0 0 - 0
NC_006089 2 79168177 C T N-Syn 1.00 MTRR c.2027C > T R676K 11 0 - 0 11 0
NC_006089 2 96844408 T G N-Syn 1.00 CEP192 c.3655 T > G K1219Q 11 0 0 11 - 0
NC_006089 2 107668292 C G N-Syn 1.00 PRKDC c.3938C > G C1313S 10 0 - 10 0 0
NC_006089 2 107767247 A G N-Syn 0.91 LOC421108 c.77A > G N26S 11 - 0 10 0 0
NC_006089 2 115050472 C A N-Syn 1.00 CSPP1 c.1303C > A H435N 10 10 - 0 0 0
NC_006089 2 120054459 T G N-Syn 1.00 FAM164A c.605 T > G V202G 10 0 0 10 - 0
NC_006089 2 126210593 G A N-Syn 0.80 C2H8orf38 c.730G > A V244I 10 8 0 - 0 0
NC_006089 2 148002272 C T N-Syn 1.00 TOP1MT c.1149C > T M383I 10 0 - 0 10 0
NC_006090 3 18177273 C T N-Syn 1.00 EPRS c.778C > T H260Y 10 0 - 0 10 0
NC_006090 3 18177438 T C N-Syn 1.00 EPRS c.943 T > C C315R 11 0 11 0 - 0
NC_006090 3 19964716 A T N-Syn 0.90 USH2A c.9152A > T E3051V 10 - 0 0 9 0
NC_006090 3 20371026 T C N-Syn 0.92 CENPF c.2726 T > C E909G 13 0 12 0 - 0
NC_006090 3 20377057 T T|A N-Syn 0.75 CENPF c.[1411 T > T] + [1411 T > A] N471N, N471Y 12 9 0 0 - 0
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Table 2 The 156 reliable marker SNPs that induced amino acid changes showing ≥10 read depths (Continued)
NC_006090 3 28850511 A G N-Syn 1.00 LOC100858112 c.586A > G F196L 10 - 0 10 0 0
NC_006090 3 47388200 G G|A N-Syn 0.77 ZC3H12D c.[998G > G] + [998G > A] T333T, T333M 13 10 0 - 0 0
NC_006090 3 48575253 C T N-Syn 0.90 SYNE1 c.11674C > T A3892T 10 0 - 0 9 0
NC_006090 3 48577869 C T N-Syn 0.93 SYNE1 c.11335C > T D3779N 14 0 - 0 13 0
NC_006090 3 54551285 T C N-Syn 1.00 PDE7B c.868 T > C T290A 11 0 11 0 - 0
NC_006090 3 66462814 C T N-Syn 1.00 LOC421765 c.1076C > T R359Q 12 0 - 0 12 0
NC_006090 3 66468226 G T N-Syn 1.00 LOC421765 c.334G > T Q112K 10 0 0 - 10 0
NC_006090 3 75929093 G A N-Syn 0.93 ZNF292 c.7835G > A T2612I 14 13 0 - 0 0
NC_006090 3 80234352 G A N-Syn 1.00 COL12A1 c.2659G > A A887T 10 10 0 - 0 0
NC_006091 4 4124961 C T Nonsense 1.00 DDX26B c.151C > T Q51. 11 0 - 0 11 0
NC_006091 4 9883806 G A N-Syn 0.91 SLITRK4 c.1715G > A R572K 11 10 0 - 0 0
NC_006091 4 49489771 G T N-Syn 0.91 RUFY3 c.1588G > T A530S 11 0 0 - 10 0
NC_006092 5 3898544 C T N-Syn 0.80 KIF18A c.1567C > T D523N 10 0 - 0 8 0
NC_006092 5 8035275 A G N-Syn 1.00 LOC100859209 c.79A > G C27R 11 - 0 11 0 0
NC_006092 5 20708767 A G N-Syn 1.00 API5 c.506A > G K169R 10 - 0 10 0 0
NC_006092 5 21158570 - A Frameshift 0.90 LOC770458 c.105- > A A35fs 10 9 0 0 0 1
NC_006092 5 22076516 T C N-Syn 1.00 C1QTNF4 c.230 T > C I77T 11 0 11 0 - 0
NC_006092 5 38183079 C T N-Syn 0.83 LOC100859479 c.82C > T P28S 12 0 - 0 10 0
NC_006092 5 44443744 G G|C N-Syn 0.75 KIAA1409 c.[2076G > G] + [2076G > C] Q692H, Q692Q 12 0 9 - 0 0
NC_006092 5 44443754 G A N-Syn 0.80 KIAA1409 c.2086G > A E696K 10 8 0 - 0 0
NC_006092 5 44443755 A T N-Syn 0.80 KIAA1409 c.2087A > T E696V 10 - 0 0 8 0
NC_006092 5 45296293 G G|A N-Syn 0.75 C5H14orf49 c.[596G > G] + [596G > A] A199A, A199V 12 9 0 - 0 0
NC_006092 5 50316949 A G N-Syn 1.00 APOPT1 c.440A > G H147R 12 - 0 12 0 0
NC_006093 6 4563260 G C N-Syn 0.90 BMS1 c.1666G > C L556V 10 0 9 - 0 0
NC_006093 6 15062678 A G N-Syn 0.80 PLAU c.925A > G W309R 10 - 0 8 0 0
NC_006093 6 25651167 G A N-Syn 1.00 RBM20 c.1687G > A D563N 10 10 0 - 0 0
NC_006093 6 30617911 C T N-Syn 0.80 ATE1 c.518C > T G173D 10 0 - 0 8 0
NC_006093 6 32898174 T C N-Syn 1.00 MKI67 c.2414 T > C M805T 10 0 10 0 - 0
NC_006094 7 9605730 T C N-Syn 1.00 ANKRD44 c.584 T > C K195R 15 0 15 0 - 0
NC_006094 7 18282262 G G|A N-Syn 0.75 LRP2 c.[3775G > G] + [3775G > A] A1259T, A1259A 12 9 0 - 0 0
NC_006094 7 21828274 A G|A N-Syn 0.75 CCDC108 c.[2902A > G] + [2902A > A] N968N, N968D 12 - 0 9 0 0
NC_006094 7 25803714 T G N-Syn 0.80 IQCB1 c.952 T > G T318P 10 0 0 8 - 0
NC_006095 8 1373656 G A N-Syn 1.00 CAMSAP1L1 c.1955G > A A652V 12 12 0 - 0 0
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Table 2 The 156 reliable marker SNPs that induced amino acid changes showing ≥10 read depths (Continued)
NC_006095 8 2290270 A G N-Syn 1.00 LOC100859900 c.65A > G L22P 13 - 0 13 0 0
NC_006095 8 2506276 C T N-Syn 1.00 CRB1 c.1814C > T S605N 12 0 - 0 12 0
NC_006095 8 2612732 T C N-Syn 1.00 ASPM c.6907 T > C C2303R 11 0 11 0 - 0
NC_006095 8 7596287 G T N-Syn 0.91 NCF2 c.1234G > T P412T 11 0 0 - 10 0
NC_006095 8 8053190 G C N-Syn 0.81 LOC768407 c.875G > C G292A 16 0 13 - 0 0
NC_006095 8 8188888 T A N-Syn 0.82 LOC768392 c.512 T > A E171V 11 9 0 0 - 0
NC_006095 8 12666139 G G|A N-Syn 0.75 ABCA4 c.[4678G > G] + [4678G > A] V1560I, V1560V 12 9 0 - 0 0
NC_006095 8 23585119 C G N-Syn 0.93 LRP8 c.583C > G G195R 14 0 - 13 0 0
NC_006096 9 800651 G G|A N-Syn 0.75 LOC424748 c.[5G > G] +
[5G > A]
R2K, R2R 12 9 0 - 0 0
NC_006096 9 2123518 A G N-Syn 1.00 YEATS2 c.602A > G N201S 11 - 0 11 0 0
NC_006096 9 4127341 G A N-Syn 1.00 GAL3ST4 c.505G > A A169T 10 10 0 - 0 0
NC_006096 9 4217231 A G N-Syn 0.92 RNF168 c.806A > G D269G 13 - 0 12 0 0
NC_006096 9 15175477 T G N-Syn 1.00 CAPN10 c.1660 T > G T554P 11 0 0 11 - 0
NC_006096 9 21419266 C A N-Syn 0.82 SPTSSB c.44C > A P15Q 11 9 - 0 0 0
NC_006097 10 3986458 T C N-Syn 0.82 VPS13C c.3727 T > C Y1243H 11 0 9 0 - 0
NC_006099 12 9103119 G A N-Syn 1.00 COPG c.1771G > A A591T 12 12 0 - 0 0
NC_006099 12 15133837 T C N-Syn 1.00 LOC100858715 c.89 T > C V30A 11 0 11 0 - 0
NC_006099 12 19738746 C T N-Syn 1.00 NR2C2 c.1061C > T S354N 10 0 - 0 10 0
NC_006100 13 2703509 A G|A N-Syn 0.77 LOC769940 c.[2875A > G] + [2875A > A] S959P, S959S 13 - 0 10 0 0
NC_006100 13 2703511 A G|A N-Syn 0.77 LOC769940 c.[2873A > G] + [2873A > A] F958S, F958F 13 - 0 10 0 0
NC_006100 13 11337736 C G N-Syn 0.90 GEMIN5 c.849C > G H283Q 10 0 - 9 0 0
NC_006100 13 11349274 A G N-Syn 0.83 GEMIN5 c.3739A > G S1247G 12 - 0 10 0 0
NC_006101 14 5552664 G A N-Syn 0.82 TEKT4 c.1192G > A V398I 11 9 0 - 0 0
NC_006101 14 5975913 T C N-Syn 0.93 CHTF18 c.1934 T > C E645G 14 0 13 0 - 0
NC_006101 14 6002290 G G|C N-Syn 0.75 MSLN c.[774G > G] + [774G > C] S258S, S258R 12 0 9 - 0 0
NC_006101 14 7697077 C T N-Syn 0.80 ABCC6 c.1213C > T V405M 10 0 - 0 8 0
NC_006101 14 13378210 T C N-Syn 0.93 C14H16orf89 c.68 T > C D23G 14 1 13 0 - 0
NC_006102 15 3706306 T C N-Syn 1.00 GLT1D1 c.968 T > C Q323R 10 0 10 0 - 0
NC_006102 15 4915706 T C N-Syn 0.90 ATP6V0A2 c.1246 T > C I416V 10 0 9 0 - 0
NC_006102 15 4926428 G A N-Syn 1.00 LOC100857705 c.1552G > A R518C 10 10 0 - 0 0
NC_006102 15 5060494 G A N-Syn 1.00 MPHOSPH9 c.755G > A R252K 14 14 0 - 0 0
NC_006102 15 5695994 G A N-Syn 0.90 WDR66 c.1690G > A D564N 10 9 0 - 0 0
NC_006102 15 6317399 C T N-Syn 1.00 C15H12orf51 c.7777C > T D2593N 10 0 - 0 10 0
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Table 2 The 156 reliable marker SNPs that induced amino acid changes showing ≥10 read depths (Continued)
NC_006102 15 6633596 T C N-Syn 1.00 USP30 c.488 T > C I163T 13 0 13 0 - 0
NC_006102 15 8096384 T C N-Syn 1.00 DDX51 c.1493 T > C M498T 11 0 11 0 - 0
NC_006102 15 8693805 G C N-Syn 1.00 RTDR1 c.118G > C V40L 10 0 10 - 0 0
NC_006104 17 6506143 T C N-Syn 0.87 SETX c.4564 T > C I1522V 15 0 13 0 - 0
NC_006104 17 6581087 G A N-Syn 1.00 C17H9orf171 c.682G > A D228N 12 12 0 - 0 0
NC_006104 17 6922987 A G N-Syn 1.00 ADAMTS13 c.3103A > G I1035V 12 - 0 12 0 0
NC_006104 17 7858127 A T N-Syn 1.00 SEC16A c.4079A > T H1360L 15 - 0 0 15 0
NC_006104 17 7905701 G C N-Syn 1.00 SNAPC4 c.2609G > C G870A 11 0 11 - 0 0
NC_006105 18 1082307 C T N-Syn 0.90 DNAH9 c.6700C > T P2234S 10 0 - 0 9 0
NC_006105 18 1111244 G A N-Syn 0.80 DNAH9 c.8491G > A V2831M 10 8 0 - 0 0
NC_006105 18 6605385 C G N-Syn 1.00 ATAD5 c.3652C > G P1218A 11 0 - 11 0 0
NC_006105 18 6605422 G A N-Syn 1.00 ATAD5 c.3689G > A R1230K 10 10 0 - 0 0
NC_006105 18 6967029 C T N-Syn 1.00 C18H17orf58 c.1018C > T L340F 12 0 - 0 12 0
NC_006106 19 5858876 T C N-Syn 1.00 ERAL1 c.1186 T > C M396V 14 0 14 0 - 0
NC_006106 19 6213750 G C N-Syn 1.00 SLC6A4 c.242G > C A81G 10 0 10 - 0 0
NC_006106 19 7495965 C G N-Syn 0.82 BRIP1 c.1718C > G P573R 11 0 - 9 0 0
NC_006107 20 12338968 T G N-Syn 0.83 CASS4 c.1169 T > G N390T 12 0 0 10 - 0
NC_006107 20 12696859 T A N-Syn 1.00 CYP24A1 c.878 T > A L293Q 12 12 0 0 - 0
NC_006108 21 2336588 G A Nonsense 0.80 TAS1R3 c.1108G > A R370. 10 8 0 - 0 0
NC_006108 21 3215527 C T N-Syn 0.92 ENO1 c.1265C > T R422H 12 0 - 0 11 0
NC_006108 21 4657639 G A N-Syn 1.00 KIAA0090 c.2716G > A R906C 11 11 0 - 0 0
NC_006110 23 5163924 T C N-Syn 1.00 ZBTB8A c.232 T > C F78L 10 0 10 0 - 0
NC_006112 25 1498400 G A N-Syn 1.00 HORMAD1 c.844G > A A282T 11 11 0 - 0 0
NC_006113 26 4679877 G A N-Syn 1.00 LOC768535 c.1097G > A P366L 10 10 0 - 0 0
NC_006127 Z 71529316 G A N-Syn 1.00 DMXL1 c.4394G > A A1465V 11 11 0 - 0 0
Contig ID, chromosome (Chr) numbers, reference position (Ref Pos), reference base (Ref Base), called (SNP) base, impact (kinds of protein mutation), SNP%, feature name (gene name), DNA change, amino acid (AA)
change, Depths, and five columns for SNP counts (cnts) are indicated.
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Table 3 Verification of 14 SNPs using PCR and Sanger sequencing in larger numbers of non-vitiliginous parental BL
(20) vs. vitiliginous SL (70) chickens
Ch Ref Pos
Ref
base
Called
base Impact
SNP
%
Feature
name
Protein
change
Results of larger population
BL (20 birds) SL (70 birds)
2 7746258 CT - FS 1 LOC100859401 Y129fs All_CT All_Del
5 21158570 - A FS 0.9 LOC770458 A35fs Ins_A_30% Ins_A_100%
9 21419266 C A N-Syn 0.82 SPTSSB [1] P15Q C:A = 3:1 C:A = 1:4
1 54936701 G T N-Syn 0.8 STAB2 A2052D All_G G:T = 1:1
3 48575253 C T N-Syn 0.9 SYNE1 A3892T C:T = 10:1 C:T = 1:10
3 18177438 T C N-Syn 1 EPRS C315R T:C = 4:1 T:C = 1:7
1 105941417 T C N-Syn 0.9 SETD4 I396V T:C = 10:1 All_C
19 5858876 T C N-Syn 1 ERAL1 M396V All_T T:C = 1:10
1 177772554 C A N-Syn 0.86 EFHA1 A220D C:A = 4:1 C:A = 1:10
1 177772568 G A N-Syn 0.86 EFHA1 V225I All_G G:A = 1:10
13 11337736 C G N-Syn 0.9 GEMIN5 H283Q All_C All_G
5 44443744 G G|C N-Syn 0.75 KIAA1409 Q692H All_G G:C = 1:10
5 44443754 G A N-Syn 0.8 KIAA1409 E696K All_G G:A = 1:4
5 44443755 A T N-Syn 0.8 KIAA1409 E696V All_A A:T = 1:4
Ratios between reference base and SNP (Called base) in large chicken populations were bolded. FS; frameshift mutation.
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populations. For this, 14 SNPs were randomly chosen
from the 156 candidate marker SNPs showing ≥10 read
depths and were subjected to SNP verification analysis
using PCR and Sanger sequencing to detect SNP posi-
tions with larger numbers of birds; specifically 20 non-
vitiliginous BL chickens and 70 SL chickens exhibiting
vitiligo. The results clearly showed differential frequen-
cies of nucleotide bases in the 14 SNP positions between
BL and SL chickens (Table 3). Thus, the 156 SNPs
known to induce amino acid changes can become poten-
tial genetic biomarkers for vitiligo in SL chickens.
Bioinformatic analyses of genes containing amino acid
change SNPs
Amino acid changes may have impacts on the functional
interpretations for vitiligo induction in SL chickens.
The Ingenuity Pathway Analysis (IPA) program gener-
ated bioinformatics data sets including functionalTable 4 Vitiligo related functions of candidate genes
Functions # molecules Genes in
Dermatological diseases/conditions 14 ADAMTS1
RNF168, S
Inflammatory response 10 ADAMTS1
Inflammatory disease 9 CBS, LRP2
Immunological disease 5 BRCA2, LR
Immune cell trafficking 2 CBS, PLAU
Infectious disease 1 PLAUgroups (gene ontology; GO) and gene networks for
genes containing amino acid changes in SL chicken.
The 156 SNPs were found in 139 genes encompassing
known- and unknown functions, chromosomal open
reading frames, and hypothetical proteins (Additional
file 2: Table S2).
Functional roles
Genes were categorized in 76 functional groups (Additional
file 3: Table S3). Of these, six functional groups are of
particular interest to autoimmune vitiligo development,
including dermatological diseases/conditions, inflam-
matory response, inflammatory disease, immunological
disease, immune cell trafficking, and infectious disease
(Table 4). The functional group of genes for dermato-
logical diseases/conditions contained the following genes:
ADAMTS13 (ADAM metallopeptidase with thrombospon-
din type 1 motif 13); ASPM [asp (abnormal spindle) homo-
log, microcephaly associated; Drosophila)]; ATP6V0A2volved
3, ASPM, ATP6V0A2, BRCA2, COL12A1, GRM5, LRP2, MKI67, OBSCN, PLAU,
TAB2, XIRP1
3, CBS, OL3A1, LRP2, LRP8, NR2C2, PDE7B, PLAU, PON2, SLC6A4
, MKI67, NCF2, NR2C2, PDE7B, PLAU, SLC6A4
P2, NR2C2,PRKDC, RNF168
Table 5 Function of candidate genes containing SNPs in CDS region related to dermatological diseases/conditions
Sub-groups Molecules
Malignant cutaneous
melanoma cancer
OBSCN [15]
- Is a RhoGEF protein that interacts with cytoskeletal calmodulin and titin and is part of the giant sarcomeric
signaling protein family of myosin light chain kinases
- Mutant human OBSCN protein (E4574K) is associated with melanoma in human.
STAB2 (or FEEL2) [16,17]
- is a large, transmembrane receptor protein which may function in angiogenesis, lymphocyte homing, cell
adhesion, or receptor scavenging.
- Somatic missense homozygous mutant human STAB2 gene (c.3862 T > G translating to p.S1288A) is associated
with melanoma in skin from human leg (observed in 2 of 2 samples)
LRP2 (or megalin) [17,18]
- Is a member of the low density lipoprotein (LDL) receptor gene family essential for brain development.
- Somatic missense heterozygous mutant human LRP2 gene (c.6284G > A translating to p.R2095Q) is associated with
melanoma in skin from human leg (observed in 2 of 2 samples).
ASPM [17,19]
- This gene is the human ortholog of the Drosophila melanogaster ’abnormal spindle’ gene (asp), which is essential
for normal mitotic spindle function in embryonic neuroblasts.
- Somatic nonsense heterozygous mutant human ASPM gene (c.7174C > T translating to p.Q2392*) is associated
with melanoma in skin from human leg (observed in 2 of 2 samples).
GRM5 [20]
- Is a member of G protein-coupled receptor that are widely expressed in the brain and modulate many diverse
signaling pathways
- In mouse melanocytes, transgenic rat GRM5 protein (S901A mutant) affects development of melanoma in mouse.
BRCA2 [21,22]
- At the cellular level, loss of BRCA2 function results in sensitivity to cross-linking agents, a decrease in homology-
directed repair of double-stranded DNA breaks (DSBs), and defects in replication and checkpoint control
- Inherited mutations in BRCA1 and this gene, BRCA2, confer increased lifetime risk of developing breast or
ovarian cancer.
- Mutant human BRCA2 gene is associated with malignant melanoma in Homo sapiens.
XIRP1 [17,23]
- Its function is unknown, but it is upregulated in wounded skeletal muscle cells in zebrafish
- Somatic nonsense heterozygous mutant human XIRP1 gene (c.2838G > A translating to p.W946*) is associated with
melanoma in skin from human leg (observed in 2 of 2 samples).
RIDDLE syndrome
RNF168 [24]
- Is an E3 ubiquitin ligase
- Mutant human RNF168 gene (deletion c.1323_1326del of ACAA and DNA duplication mutation) is associated with
RIDDLE (radiosensitivity, immunodeficiency, dysmorphic features, and learning difficulties) syndrome, which a novel
human immunodeficiency disorder associated with defective double strand break repair.
Schulman-Upshaw syndrome
ADAMTS13 [25]
- Is von Willebrand Factor (VWF) cleaving metalloproteinase.
- Is associated with the development of thrombotic thrombocytopenic purpura (TTP), known as the Schulman-
Upshaw syndrome.
- Mutant human ADAMTS13 gene (deletion c.1783_1784delTT) is associated with congenital TTP.
Autosomal recessive cutis laxa
type IIA
ATP6V0A2 [26]
- Is a subunit of the vacuolar ATPase (v-ATPase), a heteromultimeric enzyme that is essential for the acidification of
diverse cellular components.
- Mutations in human ATP6V0A2 protein (p.Q765* (rs80356758), p.R63* (rs80356750), deletion, and insertion) is
associated with autosomal recessive cutis laxa type IIA.
Wrinkly skin syndrome
ATP6V0A2 [26]
- Mutant human ATP6V0A2 gene (g.10132G > A) is associated with wrinkly skin syndrome
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Table 5 Function of candidate genes containing SNPs in CDS region related to dermatological diseases/conditions
(Continued)
Hyperpigmentation
GRM5 [20]
- In mouse melanocytes, transgenic rat mGlur5 [GRM5] protein increases hyperpigmentation of pinna in mouse ear.
Development of blister
PLAU [27,28]
- Is a serine protease involved in degradation of the extracellular matrix and possibly tumor cell migration and
proliferation.
- Heterozygous- and heterozygous mutant mouse Plg gene in mouse affects development of blister in mouse
subepidermal skin that is altered by transgenic uPAR (PLAUR) protein and transgenic uPA (product of PLAU)
protein and development of blister.
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BRCA2 (breast cancer 2, early onset); COL12A1 (collagen,
type XII, alpha 1); GRM5 (glutamate receptor, metabo-
tropic 5); LRP2 (low density lipoprotein receptor-
related protein 2); MKI67 (marker of proliferation
Ki-67); OBSCN (obscurin, cytoskeletal calmodulin and
titin-interacting RhoGEF); PLAU (plasminogen activa-
tor, urokinase); RNF168 (ring finger protein 168, E3Table 6 Associated network functions of candidate genes
ID Molecules in network S
1 26 s Proteasome, ADAMTS13, ATE1, BMPER, CAPN10, CD200R1,
CENPF, Cg, COL12A1, collagen, CTTNBP2, DBF4, ENO1, ERK1/2, FGL2,
GRM5, LDL, LRP2, LRP8, LRP, MKI67, NCF2, P38 MAPK, PDGF BB, Pkc(s),
PLAU, PON2, Ppp2c, SACS, SLC6A4, SYNE1, TAS1R3, UBASH3A, Vegf
4
2 ANKRD44, ANKRD52, API5, APOPT1, ATAD5, BMS1, C9orf114,
CAMSAP2, CCDC115, CENPQ, CEP192, CGGBP1, CPVL, DDX26B,
DNHD1, EMC1, ERAL1, ERCC6L, GTSE1, MTR, MTRR, PLK1, PPP6R1,
PRRC1, RGPD5 (includes others), RNF169, RNF219, SIMC1, SPATA2L,
STK10, STXBP4, TTC4, UBC, VRK3, ZNF292
2
3 ASPM, ATP6V0A2, ATP6V1E2, C15orf39, CCDC8, CHTF18, COPG1,
DUS2L, EARS2, EPRS, FANCB, GEMIN5, HELB, INPP5B, KAT5, OGFOD2,
PARS2, RNF168, SEC16A, SEPT3, SEPT7, SETX, SNX10, TMEM106B,
TRIM68, UBC, USP30, USP34, USP35, USP40, USP48, USP27X, USP9Y,
YEATS2, ZBTB8A
2
4 1810009J06Rik/Gm2663, ABCA4, ABCC6, ADCYAP1, BRCA1, BRIP1, Ca2
+, CASC1, DNAH9, DPP7, DQX1, Gbp8, IFNG, IL4, KIF16B, KIF18A,
LOC290071, MAPK8, MPHOSPH9, MPPE1, MYO16, NUFIP1, Pde,
PDE1C, PDE7B, PPP1CA, PSEN1, Rb, RTDR1, SLAIN1, ST18, STAB2,
TOP1MT, UTP, ZC3H12D
2
5 ABCD4, ABHD2, ADCK4, ANKRD10, AS3MT, C1QTNF4, CEP120, CLN6,
CSPP1, DDX51, DLEC1, DMXL1, DPP7, EFHA1, FASTKD1, GAL3ST4,
ILVBL, KRT12, KRT15, LRRC8A, MORC1, NR3C1, OGDHL, PEX1, SETD4,
SPTLC2, SPTLC3, SPTSSB, STAT3, TEKT4, UBC, VPS13C, XRCC6, ZFYVE28,
ZNF483
2
6 AIFM3, APP, BCL2L15, CASP3, DNAJB14, DNAJC4, DNAJC12, DNAJC19,
HORMAD1, Hsp84-2, HSP90AB1, HSPB7, HSPD1, IARS2, IQCB1, KLHL32,
MYLK4, NEK11, norepinephrine, OBSCN, OTC, RPGR, RUFY3, SMC3,
TARP, TBX22, testosterone, TGM4, THAP4, TTPA, ULK4, UNC79, USH2A,
YWHAQ, ZC2HC1A
1
7 Act1, Akt, BRCA2, CBS, CD3, CENPJ, Ck2, Collagen type I, CRB1,
CYP24A1, estrogen receptor, Immunoglobulin, INSRR, Jnk, LAG3, miR-
101-3p (and other miRNAs w/seed ACAGUAC), MSLN, MZB1, NFkB
(complex), NKTR, NR2C2, PI3K (complex), PIK3IP1, PIK3R6, PRKDC,
Prl4a1, Psg16, SEC14L2, SNAPC4, Taok2, Tnfrsf22/Tnfrsf23, TRAF1-
TRAF2-TRAF3, VTCN1, Zfp110/Zfp369, ZNF675
1
Functions associated with 7 networks are listed. Score means the number of netwoubiquitin protein ligase); STAB2 [stabilin 2 or FEEL2
(fasciclin EGF-like, laminin-type EGF-like, and link
domain-containing scavenger receptor 2)]; and XIRP1
(xin actin-binding repeat containing 1). General and
dermatological disease related functions for these
genes are summarized in Table 5.
Interestingly, a recent report by Nikolaev et al. (2012)
[17] indicated that amino acid changes found in ASPM,core
Focus
molecules Top functions
8 24 Cardiovascular Disease, Hematological Disease,
Cardiac Infarction
6 15 Cell Cycle, DNA Replication, Recombination, and
Repair, Developmental Disorder
6 15 Developmental Disorder, Endocrine System Disorders,
Hereditary Disorder
6 15 Cell Morphology, Cellular Function and Maintenance,
Hair and Skin Development and Function
0 12 Lipid Metabolism, Small Molecule Biochemistry,
Digestive System Development and Function
7 11 Hereditary Disorder, Ophthalmic Disease,
Neurological Disease
4 9 Cellular Response to Therapeutics, Cellular Assembly
and Organization, DNA Replication, Recombination,
and Repair
rk eligible molecules out of differentially expressed genes.
Figure 3 Gene network #1. Molecular interactions among important focus molecules are displayed. Gray symbols show the genes found in the
list of SNP while white symbols indicate neighboring genes that are functionally associated, but not included, in the gene list of SNP. Symbols for
each molecule are presented according to molecular functions and type of interactions.
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human melanoma by exome sequencing. Melanocytes in
vitiligo also exhibit morphological and biological melano-
cyte defects/alterations compared to melanocytes from
individuals with normal pigmentation [29]. While these
alterations may be different from those observed in mel-
anoma, e.g. slower growth, and higher sensitivity to oxi-
dative stress of cultured melanocytes [30,31], alterations
in amino acid sequences found in homolog proteins but
different residues may result in opposite phenotypes of
dermatological diseases/conditions [32]. In addition to
these molecules, BRCA2, GRM5, MKI67, and OBSCN
associated with SLV are also known to be associated
with human melanoma. The relationship between can-
didate genes and other dermatological diseases includ-
ing melanoma is summarized in Table 5.
Gene networks
Gene network analysis, which represents the intermo-
lecular connections among interacting genes based onfunctional knowledge inputs, was performed on genes
with amino acid changes in SLV chickens using the IPA
program. The gene network analysis was carried out
using the simplest setting of 35 focus molecules to
facilitate and summarize the intermolecular connections
(Table 6 and Figures 3, 4, 5, 6, 7, 8, and 9). A discussion
of the 7 gene networks is provided below and gene infor-
mation for focus molecules in each network is listed in
Additional file 4: Table S4.
Candidate genes in Network #1 are associated with
signaling pathways of the mitogen activated protein
kinase (MAPK; also ERK1/2) and protein kinase C
(Pkc) connected to VEGF (vascular endothelial growth
factor) and PDGF (platelet derived growth factor) with
PLAU in the center (Figure 3). The top functions
related to network #1 are cardiovascular disease,
hematological disease, and cardiac infarction. Interest-
ingly, molecules including LRP2, PLAU, ADAMTS13,
and GRM5 that are part of Network #1 were also iden-
tified as functional factors for melanoma as described
Figure 4 Gene network #2. Molecular interaction and symbols are the same as the description in Figure 3.
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sequence of LRP2, altered function of MAP2K1 and
MAP2K2 induced by genetic mutations in melanoma
patients [17], and mutations in GRM5 in mouse
melanoma models [20] were also reported. The con-
nections in Network #1 therefore suggest genetic muta-
tions that generated amino acid changes in LRP2, PLAU,
ADAMTS13, and GRM5 may influence dermatological
diseases, including vitiligo, through MAPK and ERK1/2
signaling pathways.
The top functions of Network #2 include Cell Cycle,
DNA Replication, Recombination and Repair, and Develop-
mental Disorder (Figure 4) and Network #3 is involved in
Developmental Disorder, Endocrine System Disorders,
Hereditary Disorder (Figure 5). Most molecules in
Networks #2 and #3 directly bind to UBC (ubiquitin C).
Ubiquitinylation, the covalent attachment of ubiquitin to
proteins, regulates numerous cellular processes such as
protein degradation and signal transduction. Recently,
many ubiquitinylated proteins and their lysine ubiquitinyla-
tion site were identified using proteomic technologies inmammalian species [33-37]. Indeed, in SLV, the amino acid
changes in lysine residues for CEP192 (centrosomal protein
192 kDa; pK169R) and API5 (apoptosis inhibitor 5;
pK1219Q) were identified (Table 2), suggesting that the
various cellular functions including protein degradation
by altered ubiquitinylation properties of proteins may play
a significant role in the induction of vitiligo.
Molecules in Network #4 are involved in Cell Morph-
ology, Cellular Function and Maintenance, Hair and Skin
Development and Function (Figure 6). Molecules in net-
work #4 mainly interact with IFNG (interferon gamma),
IL4 (interleukin 4), MAPK8, and calcium signaling path-
ways in addition to protein phosphatase (PPP1CA; protein
phosphatase 1 catalytic subunit alpha isozyme) functions.
MYO16 (myocin 16), KIF18A (kinesin family member
18A), and CASC1 (cancer susceptibility candidate 1) are
known to directly bind to PPP1CA [38-40], suggesting that
amino acid changes in those proteins may induce alter-
ations (hyper vs hypo) in protein phophorylation states in
SL chickens, resulting in vitiligo development. Molecules
interacting with IFNG, IL4, MAPK8 and calcium signaling
Figure 5 Gene network #3. Molecular interaction and symbols are the same as the description in Figure 3.
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tionship with each other making it difficult to explain how
amino acid changes in these molecules affect vitiligo induc-
tion in SL chicken.
Molecules in Network #5 also mainly bind to UBC
as discussed in Networks #2 and #3 and the functions
include Lipid Metabolism, Small Molecule Biochem-
istry, Digestive System Development and Function
(Figure 7).
Network #6 contains molecules involved in Hereditary
Disorder, Ophthalmic Disease, Neurological Disease
(Figure 8). In this network, ZC2HC1A (zinc finger,
C2HC-type containing 1A) and RUFY3 (RUN and
FYVE domain containing 3) directly bind to APP [amy-
loide beta (A4) precursor protein]. APP is a precursor
protein for beta-amyloide, which is the main constitu-
ent of amyloid plaques in the brains of Alzheimer
disease patients [41]. RUFY3 (also known as single
axon-related; singar1), which is a brain specific protein,
regulates neuronal polarity by suppressing formation of
surplus axons [42]. Though the binding of ZC2HC1A andRUFY3 to APP was found during the progression of
Alzheimer disease [41], the functional roles for this
binding in the progression of this disease has not been
characterized. Similarly, amino acid changes found in
ZC2HC1A and RUFY3 are implicated in SLV development
possibly as a result of altered APP binding properties.
USH2A [Usher syndrome 2A (autosomal recessive, mild)]
was included in network #6. Various mutations in USH2A
have been identified in patients of Usher syndrome type II,
which is characterized by moderate to severe sensorineural
hearing loss and progressive retinitis pigmentosa [43].
Vitiliginous SL chickens may also develop severe visual
impairment and blindness due to autoimmune activity
directed against choroidal melanocytes and subsequent
damage to the retinal pigment epithelium. [44,45]. Taken
together, the amino acid change in USH2A also may affect
vitiligo progression and retinal depigmentation.
Molecules in Network #7 mainly function in Cellular
Response to Therapeutics, Cellular Assembly and Or-
ganization, DNA Replication, Recombination, and Re-
pair. PRKDC (protein kinase, DNA-activated, catalytic
Figure 6 Gene network #4. Molecular interaction and symbols are the same as the description in Figure 3.
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mainly involved in this network (Figure 9). In addition
to knock-out and inactive mutations, alteration of
autophosphorylation capability by single amino acid
change of PRKDC has been known to influence rejoin-
ing of DNA double stranded breaks in mammalian
cells [46], suggesting that vitiligo development may be
affected by aberrant PRKDC kinase activity due to an
observed amino acid change.
Vitiligo susceptible loci in human populations identi-
fied by several GWAS [5-10] also showed several loci
that induced amino acid changes in various proteins
such as STRN3 (Striatin, calmodulin binding protein 3),
DNAH5 (dynein, axonemal, heavy chain 5), KIAA1005
(immunoglobulin heavy variable 3), TYR (tyrosinase),
OCA2 (oculocutaneous albinism II), PTPN22 [protein
tyrosine phosphatase, non-receptor type 22 (lymphoid)],
IFIH1 (interferon induced with helicase C domain 1),
SLA (SRC-like-adaptor), CD44, MC1R [melanocortin 1
receptor (alpha melanocyte stimulating hormone recep-
tor)], UBASH3A (ubiquitin associated and SH3 domaincontaining A), C1QTNF6 (C1Q and tumor necrosis fac-
tor related protein 6), CASP7 (caspase 7), and GZMB
(granzyme B). One similar mutation in UBASH3A pro-
tein coding region from human [6] was also found in
the SLV chicken model (Table 2). Additionally, when
the long list of 3518 candidate amino acid altering
SNPs (read depth <10) was considered, several genes,
including IFIH1 (interferon-induced helicase C domain-
containing protein 1), CD44 antigen and DNAH5
(dynein, axonemal, heavy chain 5), matched those
identified by human GWAS studies [Additional file 1:
Table S1 and [5,6]], although the amino acid position
and alterations did not match. UBASH3A is one of the
two family members belonging to the T cell ubiquitin
ligand (TULA) family and can negatively regulate T cell
signaling [47]. Together with the UBC molecule discussed
elsewhere in this paper, functions for UBASH3A related to
ubiquitinylation and T cell signaling pathway may be im-
portant for SLV development. IFIH1 encodes an interferon-
induced RNA helicase involved in antiviral innate immune
responses, associated with type 1 diabetes, Graves’ disease,
Figure 7 Gene network #5. Molecular interaction and symbols are the same as the description in Figure 3.
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CD44 encodes a cell surface glycoprotein with various func-
tions, including a role in T cell development [54], and is as-
sociated with lupus [55]. DNAH5 gene mutation is found
in patients with primary ciliary dyskinesia (PCD) [56], a rare
disease transmitted as an autosomal recessive trait and
characterized by recurrent airway infections due to abnor-
mal ciliary structure and function. Primary defects in the
structure and function of sensory and motile cilia result in
multiple ciliopathies [57].
Conclusions
In this study, various potential genetic markers showing
amino acid changes were identified in the SLV model
through genome re-sequencing. When considering func-
tionality based on the interpretation of factors involved,
development of vitiligo appeared to be associated with
the interactions among cytoskeletal factors (OBSCN,
ASPM, XIRP1, ADAMTS13), protein kinases (MAPK,
ERK1/2, PKC, PRKDC), phosphatase (PPP1CA), ubiqui-
tinylation (UBC) and amyloid (APP) production. Furtherfunctional validation study, such as allele specific expres-
sion of the candidate genes with candidate SNPs at the
target tissues involved in SLV development will be car-
ried out using the SL chicken model for spontaneous
autoimmune vitiligo.
Methods
Animals and Illumina sequencing
Adult SL chickens with vitiligo and parental non-
vitiliginous BL chickens, maintained by G. Erf at the
University of Arkansas (Fayetteville, AR), were selected
from the breeder populations. Blood (3 ml) was collected
from 12 birds each following an animal use protocol
approved by the University of Arkansas Institutional
Animal Care and Use Committee (IACUC; approval
number: 11019). Genomic DNA was isolated from each
whole blood sample using QiaAmp DNA mini kit (Qia-
gen, Hilden, Germany) following manufacturer’s instruc-
tions. DNA quality was determined by agarose gel
electrophoresis and 10 samples having the highest qual-
ity in each line were pooled to represent each line.
Figure 8 Gene network #6. Molecular interaction and symbols are the same as the description in Figure 3.
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for the pooled DNA samples were performed by the
National Center for Genome Resources (NCGR; Santa
Fe, NM). Illumina HiSeq system 2x100 bp paired end
read technology was used for genome sequencing.
Genome sequence assembly and data analysis
Illumina sequencing data received from NCGR was
aligned to the chicken reference genome sequence for
Red Jungle Fowl (GBK 4.0) that was retrieved from
NCBI. For the reference based genome alignment, the
NGen genome sequence assembly program of the Laser-
gene software package (DNAStar, Madison, WI) was
used. Assembly parameters were as follows: file format,
BAM; mer Size, 21; mer skip query, 2; minimum match
percentage, 93; maximum gap size, 6; minimum aligned
length, 35; match score, 10; mismatch penalty, 20; gap
penalty, 30; SNP calculation method, diploid bayesian;
minimum SNP percentage, 5; SNP confidence threshold,
10; minimum SNP count, 2; minimum base quality
score, 5. After assembly, the SeqMan Pro program of theLasergene package was used for further analyses includ-
ing SNP data.SNP detection and analysis
JMP genomics (SAS Institute, Inc., Cary, NC) program
was used for filtering unique SNPs for vitiligo SL chick-
ens. SNPs occurring in both SL and BL lines were fil-
tered out, leaving behind unique SNPs for each line. To
identify highly fixed and homozygous SNPs, the SNPs
were filtered based on SNP percentages (SNP%). SNPs
with a SNP% of ≥75 (%) (for example, number of SNP =
3 of read depth = 4) were chosen. The 75% cutoff for
SNP selection was set by considering potential sequen-
cing errors that can be generated by the massively paral-
lel sequencing method. Potential causal SL SNPs that
induce non-synonymous changes in CDS regions were
chosen for further analysis. Since the read depth of many
SL SNPs was low, unique SNPs showing ≥10 read depths
were considered as reliable SNPs. Reliable and causal
SNPs, which were chosen by criteria described above
Figure 9 Gene network #7. Molecular interaction and symbols are the same as the description in Figure 3.
Jang et al. BMC Genomics 2014, 15:707 Page 18 of 21
http://www.biomedcentral.com/1471-2164/15/707were confirmed by double-checking the raw assembly
data with alignment view to reduce false positives.
SNP validation using PCR and Sanger sequencing
Fourteen randomly chosen SNPs, which induce amino
acid changes in the CDS region, were subjected to val-
idation using PCR and Sanger sequencing with larger
numbers of SL and BL chickens. Twenty BL and 70 SL
chickens that were verified phenotypically to be non-
vitiliginous and vitiliginous, respectively, were used for
blood sampling. Approximately 100 μL of blood was
collected from each bird by wing vein puncture
into tubes containing citrate (anticoagulant). Genomic
DNA was isolated from whole blood using the Wizard
SV 96 Genomic DNA Purification System (Promega;
Madison, WI) following manufacturer’s instructions
with modifications. Isolated DNA was quantified using
a Nanodrop 1000 spectrophotometer (Thermo Fisher
Scientific Inc., Waltham, MA) and a dilution of 1 ng/
μL was prepared in 96 well PCR format for all samples.
For PCR reaction, forward and reverse primers weredesigned based on the RJF genome sequence (GenBank
assembly ID: GCA_000002315.2) using Primer 3 online
software (Table 7). The sequencing primers were de-
signed to anneal at least 50 bp upstream of the SNP
position and forward/reverse primers were chosen at
the flanking regions of the seq primer and the SNP
position. All primers were commercially synthesized
by Integrated DNA Technology (Ames, IA). PCR was
carried out as 25 μL reaction volumes in 96 well plates
with cyle conditions as follows: denaturation 95°C for
1 min, 40 cycles of amplification (95°C for 30 s, 55-63°C
for 1 min, 72°C for 1 min), final extension 72°C for
10 min. Verification of PCR was performed by 1% agar-
ose gel electrophoresis. PCR products were purified
using the Wizard SV 96 PCR Clean-Up System (Pro-
mega; Madison, WI) following manufacturer’s instruc-
tions. Briefly, four plates (four different PCR products)
were pooled into one plate and were subjected to PCR
clean-up. Cross-specificity of seq-primers to the four
pooled PCR products was examined by BLAST func-
tion (NCBI) and only products that were not cross-
Table 7 Primers used for PCR and Sanger sequencing
Gene Primer name Primer sequence (5′→3′)
EFHA1
Forward CAAAAACCTAAATGGGTTTCCA
Reverse AAACTTCATCAGGACATGCAGA
Sequencing GTGCAAGTTTCTGAAAGACT
EPRS
Forward CAATTCCACACTTTGCAGGTTA
Reverse GCTGTGATGCCAAATTTAAACA
Sequencing GAAGGGAAGGCATATGTGGA
ERAL1
Forward AGGACACACACATGCTGGATAC
Reverse GCCCTTTTTGTGTTTTAAGTGG
Sequencing GAGACTTCCTTGGGACCACA
LOC100859401
Forward GAATTTACCAGTCCAGGCACTC
Reverse ACTACCTTGGGCCTTGTCAGTA
Sequencing ATGCTCCTTTTTTCCAGACC
LOC770458
Forward TGCAGAGAATACAGCACGATCT
Reverse ACTCACTCCATAAGGGGAGACA
Sequencing GCCTTTACCAGACAAA
SPTSSB
Forward CTTGTTGGGAATCAGCTCTCTT
Reverse TGCCTTTGTCAATACTGTGACC
Sequencing AACGCAGAGTCCTAACGTGG
STAB2
Forward CACTGTTACTGCAGTGATGCAA
Reverse GATAGGAACAGCATCCCTAACG
Sequencing GCACTGGCACGTGTTGTTCT
SYNE1
Forward ACTCACCTTGTGGTTGGCTAGT
Reverse CCTCACTGTCTTCCTCTGCT
Sequencing CCAGCCTGCTAGACATATGT
SETD4
Forward CAAATCGTTGTCACGTTCAAGT
Reverse TTCCTTTTGGTGTGCTTCCTAT
Sequencing AGATCTTCCA AGCGTAGTGC
GEMIN5-1
Forward TAGGCTTCATTTGCTGACTCAA
Reverse TACAGCAGGAAGGAAGGATGAT
Sequencing CCCTTTCTTTTCCAAAGGTG
GEMIN5-2
Forward CCTGGGATGAGGTAGTGAAAAG
Reverse AAGCAGAAAAGCAAAAGCAGAC
Sequencing ATTCTTGGTGCTGTGGCCCG
KIAA1409_1
Forward CTTTGGGCTTAGAGAACAGCAT
Reverse AAATTCAGTGGCATTTTTGCTT
Sequencing GGGGTGGTTCTCACACATGTCA
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PCR products were subjected to Sanger sequencing
performed by the University of Arkansas DNA Re-
sources Center (Fayetteville, AR). Results were analyzed
using ABI Sequence scanner software (Life Technolo-
gies, Carlsbad, CA). Ratios of bases occurring at SNP
locations were recorded.Bioinformatics
Functional interpretation of 139 genes showing ≥75
SNP%, ≥10 read depths and non-synonymous changes
was analyzed in the context of gene ontology and mo-
lecular networks using Ingenuity Pathways Analysis
(IPA; Ingenuity Systems®; www.ingenuity.com). Since
IPA is based on human and mouse bioinformatics,
functionalities for differentially expressed genes in the
chicken were interpreted based primarily on mamma-
lian biological mechanisms. The limit of number of
molecules in the network was set to 35, leaving only
the most important molecules based on the number
of connections for each focus gene (a subset of
uploaded significant genes having direct interactions
with other genes in the database) to other significant
genes [58].Availability of supporting data
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